CRMD CorMedix Inc

Price (delayed)

$8.545

Market cap

$670.37M

P/E Ratio

3.68

Dividend/share

N/A

EPS

$2.32

Enterprise value

$637.17M

Relative Growth: Rel. Growth:
Relative Strength: Rel. Strength:
Relative Valuation: Rel. Valuation:
Relative Profitability: Rel. Profitability: 99

CorMedix Inc. is a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory diseases. The Company is focused on developing its ...

Highlights
The price to earnings (P/E) is 51% lower than the last 4 quarters average of 7.2
The revenue has grown by 28% from the previous quarter
The quick ratio rose by 42% QoQ but it fell by 33% YoY
The gross margin fell by 10% YoY and by 3.1% QoQ

Key stats

What are the main financial stats of CRMD

CRMD stock price

How has the CorMedix stock price performed over time
Intraday
3.83%
1 week
1.48%
1 month
8.16%
1 year
-30.98%
YTD
-26.53%
QTD
25.85%

Financial performance

How have CorMedix's revenue and profit performed over time
Revenue
$400.05M
Gross profit
$343.39M
Operating income
$193.67M
Net income
$181.01M
Gross margin
85.8%
Net margin
45.2%
CorMedix's operating margin has surged by 177% YoY
The company's net margin has surged by 117% YoY but it fell by 14% QoQ
The company's operating income rose by 29% QoQ
The revenue has grown by 28% from the previous quarter

Price vs fundamentals

How does CRMD's price correlate with its fundamentals

Growth

What is CorMedix's growth rate over time

Valuation

What is CorMedix stock price valuation
P/E
3.68
P/B
1.55
P/S
1.7
EV/EBIT
3.39
EV/EBITDA
3
EV/Sales
1.59
The price to earnings (P/E) is 51% lower than the last 4 quarters average of 7.2
The EPS has increased by 3.1% since the previous quarter
The P/B is 56% below the 5-year quarterly average of 3.4 and 38% below the last 4 quarters average of 2.4
CorMedix's equity has increased by 8% QoQ
The price to sales (P/S) is 100% lower than the 5-year quarterly average of 1414.6 and 57% lower than the last 4 quarters average of 3.8
The revenue has grown by 28% from the previous quarter

Efficiency

How efficient is CorMedix business performance
The return on sales has surged by 125% year-on-year but it has declined by 4.3% since the previous quarter
CorMedix's ROE has soared by 123% YoY but it has decreased by 14% from the previous quarter
The company's return on invested capital has surged by 63% YoY but it fell by 6% QoQ
The ROA has soared by 61% YoY but it has contracted by 17% from the previous quarter

Dividends

What is CRMD's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for CRMD.

Financial health

How did CorMedix financials performed over time
CRMD's total assets is 115% higher than its total liabilities
The quick ratio rose by 42% QoQ but it fell by 33% YoY
CRMD's current ratio is up by 41% since the previous quarter but it is down by 29% year-on-year
The company's debt is 67% lower than its equity
CorMedix's equity has increased by 8% QoQ
CorMedix's debt to equity has decreased by 8% QoQ

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.